Aktis Oncology, Inc. (AKTS)
NASDAQ • Healthcare
Last close at September 9, 2026 at 20:00 UTC
Metrics Over Time
Where the Money Goes
Q4 2025Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
Nov 12
in 63 daysQ4 2026% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
About Aktis Oncology, Inc.
Aktis Oncology, Inc. is a NASDAQ-listed healthcare company in biotechnology that develops targeted radiopharmaceutical therapies for cancer treatment. It operates as a clinical-stage biotech business rather than a commercial drug seller, with work centered on a proprietary miniprotein radioconjugate platform designed to create tumor-seeking medicines.
Today's Snapshot
So far today, AKTS is trading 1.8% lower at 23.62, while its sector was flat. Oppenheimer, an investment bank, began covering Aktis Oncology and said its shares should beat the market.
Trading Volume
Below 10d avg (255.7K)
78.6K
vs S&P 500 Today
Underperforming Market
-1.27%
Updated: September 10, 2026 at 16:37 UTC
Get premium market insights delivered directly to your inbox.